Trillium Therapeutics Inc (TRIL)

[DFRAI]

Tril clarification from IR

The trial of Trillium’s TTI-621 in relapsed or refractory hematologic malignancies is currently in the phase 1a escalation phase and data will be reported in December at ASH 2016. Once MTD has been established the trial will transition to the cohort expansion phase. Data from the heme cohort expansion phase 1b will be provided in 2H/2017. In addition to the five sites involved in the phase 1a, the company envisions adding at least 5-7 additional sites, but have yet to decide where.

Separately, Trillium announced last month that the FDA has provided the company clearance to initiate a Phase 1 clinical trial of its lead drug candidate, TTI- 621, in solid tumors and mycosis fungoides. The company anticipates providing an update on that trial in 2H/2017.